Exact Sciences (Exact Sciences) Earnings per Share (Diluted) : $-1.14 (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences Earnings per Share (Diluted)?

Exact Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.27. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.14.

Exact Sciences's EPS (Basic) for the three months ended in Dec. 2023 was $-0.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.14.

Exact Sciences's EPS without NRI for the three months ended in Dec. 2023 was $-0.41. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.35.

During the past 3 years, the average EPS without NRIGrowth Rate was 29.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was -10.10% per year.

During the past 13 years, Exact Sciences's highest 3-Year average EPS without NRI Growth Rate was 38.40% per year. The lowest was -66.50% per year. And the median was 10.90% per year.

Exact Sciences Earnings per Share (Diluted) Historical Data

The historical data trend for Exact Sciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Earnings per Share (Diluted) Chart

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-1.62

-5.45

-3.48

-3.54

-1.13

Exact Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.72	-0.42	-0.45	-	-0.27

Competitive Comparison of Exact Sciences's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, Exact Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Sciences's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's PE Ratio falls into.

Exact Sciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Exact Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-204.149	-	0)	/	180.144
	=	-1.13

Exact Sciences's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-49.766	-	0)	/	181.125
	=	-0.27

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.14

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Exact Sciences (NAS:EXAS) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Exact Sciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (Exact Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

EXK:Germany

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.

Executives

Brian Baranick	officer: Gen. Mgr., Precision Oncology	441 CHARMANY DRIVE, MADISON WI 53719
Sarah Condella	officer: SVP, Human Resources	441 CHARMANY DRIVE, MADISON WI 53719
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Everett Cunningham	officer: Chief Commercial Officer	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeffrey Thomas Elliott	officer: Chief Financial Officer	5505 ENDEAVOR LANE, MADISON WI 53719
James Edward Doyle	director	5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott	officer: General Counsel	5505 ENDEAVOR LANE, MADISON WI 53719
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Jacob A Orville	officer: General Manager, New Ventures	5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy	director, officer: Vice President	5505 ENDEAVOR LANE, MADISON WI 53719
D Scott Coward	officer: SVP and General Counsel	441 CHARMANY DRIVE, MADISON WI 53719
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard	officer: SVP, Chief Scientific Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Torsten Hoof	officer: General Manager, International	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063